Acceleron Pharma Stock Forecast, Price & News

+0.92 (+0.72 %)
(As of 06/18/2021 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
Volume578,708 shs
Average Volume348,372 shs
Market Capitalization$7.78 billion
P/E RatioN/A
Dividend YieldN/A
30 days | 90 days | 365 days | Advanced Chart
Receive XLRN News and Ratings via Email

Sign-up to receive the latest news and ratings for Acceleron Pharma and its competitors with MarketBeat's FREE daily newsletter.

Acceleron Pharma logo

About Acceleron Pharma

Acceleron Pharma Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics to treat serious and rare diseases. It offers REBLOZYL (luspatercept-aamt), a first-in-class erythroid maturation agent, for the treatment of anemia in adult patients with beta-thalassemia and transfusion-dependent anemia. The company is also developing Sotatercept, an activin receptor type IIA fusion protein, for the treatment of patients with pulmonary arterial hypertension; ACE-1334, a pulmonary therapeutic candidate that is in Phase I clinical trials; and luspatercept-aamt for non-transfusion-dependent beta-thalassemia patients and lower-risk myelodysplastic syndrome patients. It has a license agreements with the Salk Institute for Biological Studies for the cloning of type II activin receptors; and license agreement with Fulcrum Therapeutics, Inc. to identify small molecules designed to modulate specific pathways associated with a targeted indication within the pulmonary disease space. The company was formerly known as Phoenix Pharma, Inc. Acceleron Pharma Inc. was incorporated in 2003 and is headquartered in Cambridge, Massachusetts.


See More Headlines

Industry, Sector and Symbol

Sales & Book Value






Overall MarketRank

1.54 out of 5 stars

Medical Sector

518th out of 2,100 stocks

Biological Products, Except Diagnostic Industry

73rd out of 198 stocks

Analyst Opinion: 2.4Community Rank: 3.0Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.6 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles

Acceleron Pharma (NASDAQ:XLRN) Frequently Asked Questions

Is Acceleron Pharma a buy right now?

14 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Acceleron Pharma in the last twelve months. There are currently 3 hold ratings, 10 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Acceleron Pharma stock.
View analyst ratings for Acceleron Pharma
or view top-rated stocks.

What stocks does MarketBeat like better than Acceleron Pharma?

Wall Street analysts have given Acceleron Pharma a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Acceleron Pharma wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Acceleron Pharma's next earnings date?

Acceleron Pharma is scheduled to release its next quarterly earnings announcement on Thursday, August 5th 2021.
View our earnings forecast for Acceleron Pharma

How were Acceleron Pharma's earnings last quarter?

Acceleron Pharma Inc. (NASDAQ:XLRN) released its earnings results on Wednesday, May, 5th. The biopharmaceutical company reported ($1.05) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.83) by $0.22. The biopharmaceutical company had revenue of $24.76 million for the quarter, compared to the consensus estimate of $30.15 million. Acceleron Pharma had a negative net margin of 158.11% and a negative trailing twelve-month return on equity of 23.81%. The company's quarterly revenue was up 469.9% on a year-over-year basis. During the same quarter last year, the company posted ($0.95) earnings per share.
View Acceleron Pharma's earnings history

How has Acceleron Pharma's stock price been impacted by Coronavirus?

Acceleron Pharma's stock was trading at $84.39 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, XLRN shares have increased by 52.0% and is now trading at $128.24.
View which stocks have been most impacted by COVID-19

What price target have analysts set for XLRN?

14 brokers have issued twelve-month price targets for Acceleron Pharma's shares. Their forecasts range from $99.00 to $200.00. On average, they anticipate Acceleron Pharma's share price to reach $148.21 in the next year. This suggests a possible upside of 15.6% from the stock's current price.
View analysts' price targets for Acceleron Pharma
or view top-rated stocks among Wall Street analysts.

Who are Acceleron Pharma's key executives?

Acceleron Pharma's management team includes the following people:
  • Mr. Habib J. Dable, CEO, Pres & Director (Age 52, Pay $1.26M)
  • Mr. Kevin F. McLaughlin, Sr. VP, CFO & Treasurer (Age 65, Pay $712.08k)
  • Mr. Adam M. Veness Esq., Sr. VP, Gen. Counsel & Sec. (Age 35, Pay $690.62k)
  • Mr. Sujay R. Kango, Exec. VP & Chief Commercial Officer (Age 57, Pay $702.16k)
  • Dr. Jay T. Backstrom M.D., M.P.H., Exec. VP of R&D (Age 66, Pay $850k)
  • Dr. Thomas P. Maniatis, Co-Founder, Member of Scientific Advisory Board & Director Emeritus (Age 78)
  • Dr. Mark Ptashne, Co-Founder and Member of Scientific Advisory Board
  • Ms. Lisa Wyman, Sr. VP of Technical Operations
  • Dr. Ravindra Kumar, Chief Scientific Officer & Sr. VP (Age 61)
  • Mr. Todd James IRC, Sr. VP of Corp. Affairs & Investor Relations

What is Habib Dable's approval rating as Acceleron Pharma's CEO?

11 employees have rated Acceleron Pharma CEO Habib Dable on Habib Dable has an approval rating of 100% among Acceleron Pharma's employees. This puts Habib Dable in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

Who are some of Acceleron Pharma's key competitors?

What other stocks do shareholders of Acceleron Pharma own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Acceleron Pharma investors own include Bristol-Myers Squibb (BMY), Advanced Micro Devices (AMD), Gilead Sciences (GILD), NVIDIA (NVDA), Incyte (INCY), Intel (INTC), Pfizer (PFE), Corcept Therapeutics (CORT), Cisco Systems (CSCO) and Regeneron Pharmaceuticals (REGN).

What is Acceleron Pharma's stock symbol?

Acceleron Pharma trades on the NASDAQ under the ticker symbol "XLRN."

Who are Acceleron Pharma's major shareholders?

Acceleron Pharma's stock is owned by many different retail and institutional investors. Top institutional investors include Price T Rowe Associates Inc. MD (8.83%), BlackRock Inc. (7.63%), Janus Henderson Group PLC (3.09%), Darwin Global Management Ltd. (2.48%), Bamco Inc. NY (1.88%) and Artisan Partners Limited Partnership (1.61%). Company insiders that own Acceleron Pharma stock include Adam M Veness, Corp /De/ Celgene, Habib J Dable, Jean George, John D Quisel, Joseph S Zakrzewski, Kevin F Mclaughlin, Ravindra Kumar, Sujay Kango, Terrence C Kearney and Thomas A Mccourt.
View institutional ownership trends for Acceleron Pharma

Which institutional investors are selling Acceleron Pharma stock?

XLRN stock was sold by a variety of institutional investors in the last quarter, including Lord Abbett & CO. LLC, Artisan Partners Limited Partnership, Deerfield Management Company L.P. Series C, Cormorant Asset Management LP, TimesSquare Capital Management LLC, UBS Asset Management Americas Inc., Putnam Investments LLC, and Kennedy Capital Management Inc.. Company insiders that have sold Acceleron Pharma company stock in the last year include Adam M Veness, Corp /De/ Celgene, Habib J Dable, Joseph S Zakrzewski, Kevin F Mclaughlin, Sujay Kango, Terrence C Kearney, and Thomas A Mccourt.
View insider buying and selling activity for Acceleron Pharma
or view top insider-selling stocks.

Which institutional investors are buying Acceleron Pharma stock?

XLRN stock was bought by a variety of institutional investors in the last quarter, including Darwin Global Management Ltd., Eversept Partners LP, Oak Ridge Investments LLC, Bamco Inc. NY, Holocene Advisors LP, Bank of New York Mellon Corp, Janus Henderson Group PLC, and Woodline Partners LP.
View insider buying and selling activity for Acceleron Pharma
or or view top insider-buying stocks.

How do I buy shares of Acceleron Pharma?

Shares of XLRN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Acceleron Pharma's stock price today?

One share of XLRN stock can currently be purchased for approximately $128.24.

How much money does Acceleron Pharma make?

Acceleron Pharma has a market capitalization of $7.78 billion and generates $92.52 million in revenue each year. The biopharmaceutical company earns $-166,030,000.00 in net income (profit) each year or ($2.92) on an earnings per share basis.

How many employees does Acceleron Pharma have?

Acceleron Pharma employs 312 workers across the globe.

What is Acceleron Pharma's official website?

The official website for Acceleron Pharma is

Where are Acceleron Pharma's headquarters?

Acceleron Pharma is headquartered at 128 SYDNEY STREET, CAMBRIDGE MA, 02139.

How can I contact Acceleron Pharma?

Acceleron Pharma's mailing address is 128 SYDNEY STREET, CAMBRIDGE MA, 02139. The biopharmaceutical company can be reached via phone at 617-649-9200 or via email at [email protected]

This page was last updated on 6/19/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.